{
  "company_name": "Krystal Biotech",
  "overview": "Krystal Biotech is focused on developing gene therapies for dermatological diseases. They have expanded into oncology, with a Phase 2 study of KB707, a checkpoint inhibitor, for cancer treatment.",
  "location": "Pittsburgh, Pennsylvania, United States",
  "website": "https://www.krystalbio.com",
  "therapeutic_areas": [
    "dermatology",
    "oncology"
  ],
  "clinical_trials": {
    "phase_2_failed": [
      {
        "nct_id": null,
        "title": "Phase 2 study of KB707",
        "condition_or_disease": "Cancer",
        "intervention_name": "KB707",
        "phase": null,
        "status": "Halted",
        "sponsor": "Krystal Biotech",
        "why_stopped": "FDA 'Uncertainty'",
        "completion_date": null
      }
    ],
    "phase_3_failed": [],
    "dormant_assets": []
  },
  "drug_assets": [
    {
      "name": "KB707",
      "modality": "gene therapy",
      "indication": "Cancer",
      "development_stage": "phase 2",
      "target": null
    }
  ],
  "decision_makers": [
    {
      "name": "Krish Krishnan",
      "role": "Chairman/CEO at Krystal Biotech, Inc. ...",
      "linkedin_url": "https://www.linkedin.com/in/krish-krishnan-3a0b43115",
      "email": null,
      "source": "serpapi"
    },
    {
      "name": "Suma Krishnan",
      "role": "Founder & President at Krystal Biotech, Inc.",
      "linkedin_url": "https://www.linkedin.com/in/suma-krishnan-781130116",
      "email": null,
      "source": "serpapi"
    },
    {
      "name": "David C.",
      "role": "Krystal Biotech, Inc.",
      "linkedin_url": "https://www.linkedin.com/in/davidchienmd",
      "email": null,
      "source": "serpapi"
    },
    {
      "name": "Andy Orth",
      "role": "Krystal Biotech, Inc.",
      "linkedin_url": "https://www.linkedin.com/in/andy-orth-87822a6",
      "email": null,
      "source": "serpapi"
    },
    {
      "name": "David Sweet MD, PhD",
      "role": "Director of Clinical Development at ...",
      "linkedin_url": "https://www.linkedin.com/in/dsweetmdphd",
      "email": null,
      "source": "serpapi"
    }
  ],
  "investors": [],
  "fit_score_for_convexia": 75,
  "reason_for_fit_score": "Krystal Biotech's halt of the KB707 trial due to FDA 'uncertainty' suggests potential for reevaluation with a refined regulatory strategy, aligning with Convexia's expertise in navigating trial and regulatory challenges.",
  "data_sources_used": [
    "https://www.oncologynewscentral.com/oncology/halted-trials-patient-deaths-and-more-recent-new-on-oncology-research-concerns"
  ],
  "last_updated": "2025-11-17 22:51:32.345013"
}